Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 325 (5939), 490-3

Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects

Affiliations
Randomized Controlled Trial

Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects

Rainer Rupprecht et al. Science.

Erratum in

  • Science. 2009 Aug 28;325(5944):1072. Dosage error in article text

Abstract

Most antianxiety drugs (anxiolytics) work by modulating neurotransmitters in the brain. Benzodiazepines are fast and effective anxiolytic drugs; however, their long-term use is limited by the development of tolerance and withdrawal symptoms. Ligands of the translocator protein [18 kilodaltons (kD)] may promote the synthesis of endogenous neurosteroids, which also exert anxiolytic effects in animal models. Here, we found that the translocator protein (18 kD) ligand XBD173 enhanced gamma-aminobutyric acid-mediated neurotransmission and counteracted induced panic attacks in rodents in the absence of sedation and tolerance development. XBD173 also exerted antipanic activity in humans and, in contrast to benzodiazepines, did not cause sedation or withdrawal symptoms. Thus, translocator protein (18 kD) ligands are promising candidates for fast-acting anxiolytic drugs with less severe side effects than benzodiazepines.

Similar articles

See all similar articles

Cited by 102 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback